)
)
)
Acurex Biosciences Corporation
Acurex Biosciences is a San Francisco Bay Area biotech focused on stopping the progression of neurodegenerative diseases. Spun out of Stanford University, our platform uses a proprietary method to discover new druggable targets and biomarker signatures specific to Parkinson’s disease (PD) and ALS. From our platform, we are currently developing two leading therapeutic programs:
15-Lipoxygenase inhibitor CU-13001 (Lead Program): An oral, BBB-penetrant 15-lipoxygenase inhibitor designed for treating Parkinson’s disease and ALS. We have completed 28-day IND-enabling pharmacology and toxicity studies and plan to submit an IND in 2026. As a 15-LO inhibitor, CU-13001 is the most potent anti-ferroptotic compound publicly reported so far, and its utility may extend to other non-CNS indications.
T-type calcium channel antagonist CU-00048: developed to treat Essential Tremor (ET). After completing 2-week toxicology studies, we intend to submit the IND in early 2027.
Address
San CarlosCalifornia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)